



## Iovance Biotherapeutics to Present at Two Investor Conferences in September

August 29, 2018

SAN CARLOS, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management will present at two investor conferences in September:

- **2018 H.C. Wainwright Annual Global Investment Conference** in New York, NY on Wednesday, September 5, 2018 at 10:50 a.m. ET
- **Wells Fargo Securities 2018 Healthcare Conference** in Boston, MA on Thursday, September 6, 2018 at 1:55 p.m. ET

A live audio webcast of both presentations will be available by visiting the Investors section of Iovance Biotherapeutics' website at <http://ir.iovance.com/>. A replay of the webcasts will be archived on Iovance Biotherapeutics' website for 30 days following the presentations.

### About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck, recurrent, metastatic or persistent cervical cancer, and locally advanced or metastatic non-small cell lung cancer. For more information, please visit <http://www.iovance.com>.

### Investor Relations Contact:

Sarah McCabe  
Stern Investor Relations, Inc.  
212-362-1200  
[sarah@sternir.com](mailto:sarah@sternir.com)

### Media Contact:

John Capodanno  
FTI Consulting  
212-850-5705  
[john.capodanno@fticonsulting.com](mailto:john.capodanno@fticonsulting.com)



Iovance Biotherapeutics, Inc.